阿戈美拉汀治疗抑郁症伴失眠的效果

Effect of Agomelatine in the treatment of depression accompanied with insomnia

目的探讨阿戈美拉汀治疗抑郁症伴失眠患者的效果。方法选取2015年12月～2017年6月我院门诊治疗的88例抑郁症伴失眠患者作为研究对象,按照随机数字表法将其分为对照组和阿戈美拉汀组,每组各44例。对照组患者给予帕罗西汀治疗,阿戈美拉汀组患者采用阿戈美拉汀治疗。比较两组患者的治疗总有效率及药物不良反应总发生率,并观察两组患者干预前及干预8周后的汉密尔顿抑郁量表-17项(HAMD-17)评分、匹兹堡睡眠质量指数(PSQI)评分、生活质量调查表(SF-36)评分。结果阿戈美拉汀组患者的治疗总有效率高于对照组,差异有统计学意义(P<0.05)。两组患者干预前的HAMD、PSQI评分、SF-36评分比较,差异无统计学意义(P>0.05);两组患者干预后的HAMD、PSQI评分均显著低于干预前,SF-36评分显著高于干预前,差异有统计学意义(P<0.05);阿戈美拉汀组患者干预后的HAMD、PSQI评分均显著低于对照组,SF-36评分显著高于对照组,差异有统计学意义(P<0.05)。阿戈美拉汀组患者的不良反应总发生率(9.09%)与对照组(11.36%)比较,差异无统计学意义(P>0.05)。结论临床采用阿戈美拉汀治疗抑郁症伴失眠的效果肯定,可明显改善患者的抑郁、睡眠和生活质量,增加阿戈美拉汀用药未显著增加不良反应发生率,具有较高的安全性。

Objective To investigate the effect of Agomelatine in the treatment of depression accompanied with insomnia.Methods A total of 88 depression patients accompanied with insomnia treated in outpatient department of our hospital from December 2015 to June 2017 were selected as research objects and they were divided into the control group and the agomelatine group according to the random number table method.In the control group,patients were treated with Paroxetine,while in the agomelatine group,patients were treated with Agomelatine.The total effective rate of treatment and the total incidence of adverse drug reactions between the two groups were compared.And the Hamilton depression scale-17(HAMD-17)scores,the Pittsburgh sleep quality index(PSQI)scores,and the quality of life questionnaire(SF-36)scores were observed before and 8 weeks after intervention.Results The total effective rate of treatment in the agomelatine group was higher than that in the control group,and the difference was statistically significant(P<0.05).There were no significant differences in the HAMD,PSQI and SF-36 scores between the two groups before the intervention(P>0.05).The HAMD and PSQI scores after the intervention of the two groups were significantly lower than those before the intervention,the SF-36 score was significantly higher than that before the intervention,and the differences were statistically significant(P<0.05).The HAMD and PSQI scores after the intervention in the agomelatine group were significantly lower than those in the control group,the SF-36 score was significantly higher than that in the control group,and the differences were statistically significant(P<0.05).The total incidence of adverse reactions in the agomelatine group(9.09%)was not significantly different from that in the control group(11.36%)(P>0.05).Conclusion The clinical application of Agomelatine in the treatment of depression accompanied with insomnia obtains an affirmative effect,which can significantly improve depression,sleep and quality of life.In addition,increasing the dosage of Agomelatine doesn′t increase the incidence rate of adverse reactions,with high safety.